Myristoyl Pentapeptide-17

CosmeticCosmetic lash and brow peptideExperimental

Myristoyl Pentapeptide-17 is a cosmetic lash and brow peptide. Attachment of a myristoyl fatty acid chain increases lipophilicity and is intended to improve penetration into the follicular unit. The peptide is reported by suppliers to influence keratin gene expression in the hair follicle.

Calculate Dose

For research use only.

Key Facts

CAS
959610-30-1
Molecular Weight (MW)
796.1 g/mol
Half-life
โ€”
FDA status
Not Approved
Administration Route
topical
Frequency
โ€”
Last updated
Aug 30, 2026
Reviewed
Aug 30, 2026

Research summary

Lipidated pentapeptide used in eyelash and eyebrow conditioning products. Regulated as a cosmetic ingredient; not FDA-approved as a drug and not equivalent to prostaglandin analog lash treatments.

Peptide Library's Myristoyl Pentapeptide-17 profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Protocol

Dosage Range
โ€”
Frequency
โ€”
Cycle
โ€”
Administration Route
topical
Reconstitution Guide
โ€”

Sequence & molecular data

Sequence and molecular data for Myristoyl Pentapeptide-17
Molecular formulaC41H81N9O6
Molecular weight796.1 g/mol
CAS number959610-30-1
PubChem CID127264611

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Attachment of a myristoyl fatty acid chain increases lipophilicity and is intended to improve penetration into the follicular unit. The peptide is reported by suppliers to influence keratin gene expression in the hair follicle. Published independent evidence is limited, and its mechanism is entirely distinct from the prostaglandin F2-alpha analogs used in prescription lash products.

Regulatory & research status

Myristoyl Pentapeptide-17 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Myristoyl Pentapeptide-17
FDA statusNot Approved
Research statusResearch-only compound; no approval pathway listed
AvailabilityOTC / Supplement
WADA (sport)Unknown / Not Listed
Library classificationResearch-Only

Benefits

โ€”

Potential Side Effects

No side effects listed yet for this entry.

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freezeโ€“thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Cosmetic peptides in this library are formulated into topical products; follow the product label rather than the reconstitution guidance above.

Read the full guide: how to store peptides before and after reconstitution โ†’

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544โ€“575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

Myristoyl Pentapeptide-17: frequently asked questions

What is Myristoyl Pentapeptide-17?

Lipidated pentapeptide used in eyelash and eyebrow conditioning products. Regulated as a cosmetic ingredient; not FDA-approved as a drug and not equivalent to prostaglandin analog lash treatments.

How does Myristoyl Pentapeptide-17 work?

Attachment of a myristoyl fatty acid chain increases lipophilicity and is intended to improve penetration into the follicular unit. The peptide is reported by suppliers to influence keratin gene expression in the hair follicle.

Is Myristoyl Pentapeptide-17 FDA approved?

No. Myristoyl Pentapeptide-17 is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What peptides are similar to Myristoyl Pentapeptide-17?

Compounds most often compared with Myristoyl Pentapeptide-17 include Acetyl Tetrapeptide-3, Biotinoyl Tripeptide-1, Decapeptide-12 and Palmitoyl Hexapeptide-12. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial ยท Reviewed Aug 30, 2026 ยท Updated Aug 30, 2026 ยท Version 1

This Myristoyl Pentapeptide-17 profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy ยท How profiles are compiled ยท Report an error

Track Myristoyl Pentapeptide-17 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android โ†’